Dapagliflozin/saxagliptin
Combination of | |
---|---|
Dapagliflozin | SGLT-2 inhibitor |
Saxagliptin | Dipeptidyl peptidase-4 inhibitor |
Clinical data | |
Trade names | Qtern |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]
Medical uses
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
- to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.[3]
- when already being treated with saxagliptin and dapagliflozin.[3]
References
- ^ a b "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
- ^ a b c d e "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
- ^ a b c d e f g h "Qtern EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.
External links
- "Dapagliflozin propanediol". Drug Information Portal. U.S. National Library of Medicine.
- "Saxagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Dapagliflozin". MedlinePlus.
- "Saxagliptin". MedlinePlus.
- Articles with short description
- Short description matches Wikidata
- Articles lacking reliable references from July 2020
- All articles lacking reliable references
- Use dmy dates from July 2020
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Adamantanes
- Drugs developed by AstraZeneca
- Carboxamides
- Chloroarenes
- Combination diabetes drugs
- Dipeptidyl peptidase-4 inhibitors
- Glucosides
- Nitriles
- Nitrogen heterocycles
- Phenol ethers
- SGLT2 inhibitors
- Tertiary alcohols
- All stub articles
- Gastrointestinal system drug stubs